KVUE vs PBH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

KVUE is the larger of the two ($37.11B market cap): the incumbent the market prices for continued execution (15.58x forward earnings, beta 0.40). PBH is the smaller challenger ($2.06B), cheaper on forward earnings (8.54x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

KVUE vs PBH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricKVUEPBHWhat it tells you
Market cap$37.11B$2.06BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E15.588.54Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E21.9413.41Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.400.29Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range80% of range6% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book3.651.06How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: PBH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how KVUE and PBH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KVUE and PBH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KVUE and PBH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Kenvue (KVUE) do?

Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023, and it is now in the process of being acquired by Kimberly-Clark, the maker of Huggies, Kleenex, and Kotex. The two companies signed a merger agreement on November 2, 2025 under which each Kenvue share is to be converted into $3.50 in cash plus 0.14625 of a Kimberly-Clark share, a combination valued at about $48.7 billion when it was announced. In October 2026 the European Commission approved the deal on condition that Kimberly-Clark sell its Kotex, Camelia, and Record feminine-hygiene brands in the European Economic Area (to Dilek Grup), and in August 2026 Kenvue agreed to sell its feminine-care business in Brazil to Essity for about $284 million, a sale Brazil's competition authority has cleared. On September 28, 2026 Kimberly-Clark launched exchange offers for up to $7.0 billion of Kenvue notes, conditioned on the merger, which it expects to complete in the fourth quarter of calendar 2026.

Full KVUE guide

What does Prestige Consumer Healthcare (PBH) do?

Prestige Consumer Healthcare Inc. owns over-the-counter healthcare brands rather than inventing them. The portfolio spans Monistat and Summer's Eve in women's health, BC and Goody's pain powders, Clear Eyes and TheraTears eye care, Dramamine, Fleet, Chloraseptic, Luden's, DenTek, Compound W, Nix, Debrox and Boudreaux's Butt Paste, plus Gaviscon in Canada and Hydralyte and the newly acquired Dermal Therapy line in Australia. Most manufacturing is outsourced, so spending goes to advertising and shelf presence instead of factories. Two segments carry the results: North American OTC Healthcare produced about $226 million of the June 2026 quarter's roughly $266 million, and International OTC Healthcare the remaining $40 million. Concentration is real on both ends, with the top five brands at about 39 percent of gross revenue, Walmart at roughly 19 percent and Amazon at roughly 16 percent. The fiscal year ends in March, so the quarter reported on August 6, 2026 was the first of fiscal 2027.

Full PBH guide

KVUE vs PBH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • KVUE drivers: What holders receive at closing; Regulatory path and timing.
  • PBH drivers: The biggest acquisition in years just closed; Organic growth returned, reported gross margin did not.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The main risks are now deal risks. For PBH, clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project.

KVUE or PBH: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KVUE if you believe its drivers more; PBH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KVUE and PBH guides.

KVUE vs PBH: the full fundamentals

KVUE. Kenvue no longer trades on its own fundamentals: with a signed merger agreement and conditional EU approval, the KVUE price reflects $3.50 of cash plus 0.14625 of a Kimberly-Clark share, minus a discount for time and the chance the deal fails. The trailing and forward multiples above describe the business Kimberly-Clark is buying rather than what drives the stock day to day.

PBH. Fiscal 2026, which ended March 31, 2026, brought revenue of about $1,088.7 million against about $1,137.8 million the year before, so the trailing figure reflects a down year already in the base. At about 14 times trailing and 10 times forward earnings as of October 16, 2026, the stock looks undemanding next to consumer staples generally, and the reason is visible on the balance sheet: enterprise value including roughly $2.0 billion of net debt is a very different number from the roughly $2.37 billion equity value. Guidance for fiscal 2027 is not comparable to fiscal 2026 without adjustment, because it folds in two acquisitions that closed in June and July 2026; analysts expect the November 5 report to show about $329 million of revenue and $1.07 of adjusted EPS.

Headline figures (approximate, October 2026): KVUE shows deal consideration (per kvue share) $3.50 cash + 0.14625 KMB shares, expected closing Q4 2026 (per Kimberly-Clark), revenue (ttm) ~$15.4 billion (Q2 up ~3% YoY), net income (ttm) ~$1.66 billion; PBH shows revenue (ttm) ~$1.10B, through the quarter ended June 30, 2026, latest quarter (q1 fy2027) ~$265.7M revenue, up ~6.5%, with ~3.2% organic growth, diluted eps (q1 fy2027) ~$0.61 GAAP and ~$0.98 adjusted, versus ~$0.88 expected, margins and net income (ttm) Gross ~55%, operating ~21%; net income ~$172M.

The bottom line: KVUE vs PBH

KVUE and PBH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KVUE and PBH exposure against your real portfolio. It is not an investment adviser.

Wondering how KVUE or PBH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Kenvue

Ask Walnut's AI anything about KVUE and see how it fits what you own.

FAQ

What is the difference between KVUE and PBH?

+

Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023, and it is now in the process of being acquired by Kimberly-Clark, the maker of Huggies, Kleenex, and Kotex. Prestige Consumer Healthcare Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is KVUE or PBH the better stock?

+

Neither is universally better. KVUE is the larger incumbent; PBH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, KVUE or PBH?

+

On forward P/E (as of November 2026), KVUE trades at 15.58x and PBH at 8.54x, so PBH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both KVUE and PBH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of KVUE vs PBH?

+

KVUE: The main risks are now deal risks. Closing could be delayed or fail if remaining regulatory conditions are not met, and a failed deal would likely send KVUE back toward a standalone valuation. Because most of the consideration is Kimberly-Clark stock, a fall in KMB shares directly lowers what a Kenvue holder receives; Kimberly-Clark shares had fallen about 13% according to an October 2026 report. The combined company takes on Kenvue's inherited litigation, including Tylenol and talc-related claims, plus integration risk and added debt from the cash portion. Until closing, Kenvue's own operations still carry private-label competition, input-cost inflation, and currency exposure, and its latest quarter showed only about 3% revenue growth with EPS slightly below estimates. PBH: Clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. Net debt of roughly $2.0 billion now sits close to the entire equity market value, and first-quarter interest expense of about $13.9 million reflected only a few weeks of the new term loan, so the run-rate cost of that debt is materially higher from here. Customer concentration cuts both ways: Walmart was roughly 19 percent of gross revenue last quarter and Amazon roughly 16 percent, and Amazon also sells competing house-brand versions of several categories Prestige plays in. Private label and store brands, supplied at scale by Perrigo and sold as Equate, Up and Up and Amazon Basic Care, price against Prestige's brands directly whenever household budgets tighten. Several plaintiff law firms announced investigations after the May 13, 2026 fiscal 2026 results, though as of the Form 10-Q filed August 6, 2026 no securities class action with a case number had been filed and the company disclosed only routine legal matters. The stock has fallen about 18 percent in 2026 and trades well below the mean target of the five analysts who cover it (about $67.80), a gap that reflects doubt about how quickly the debt comes down.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell KVUE or PBH; figures are approximate and dated (as of November 2026). Verify current data before investing.